Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 13, 2019 - Issue
Submit an article Journal homepage
120
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study

Jindi Zhang1 Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Pudong, Shanghai200126, People’s Republic of China;2 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-6559-977X
ORCID Icon,
Anyang Li2 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, People’s Republic of China
,
Qi Jiang2 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, People’s Republic of China
,
Feiyun Zheng2 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, People’s Republic of China
&
Haiyan Zhu1 Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Pudong, Shanghai200126, People’s Republic of China;2 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, People’s Republic of ChinaCorrespondence[email protected]
Pages 3913-3918 | Published online: 15 Nov 2019

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Qingli Cui, Yanhui Hu, Dongyang Ma & Huaimin Liu. (2021) A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer. Drug Design, Development and Therapy 15, pages 339-347.
Read now

Articles from other publishers (6)

Aizhi Geng, Hailei Yang, Zhenfeng Wang & Chuanzhong Wu. (2022) Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum‐resistant recurrent ovarian cancer treatment: A retrospective cohort study. Journal of Clinical Pharmacy and Therapeutics 47:12, pages 2264-2273.
Crossref
Ya-Nan Wan, Hai-Ming Chen, Xin-Fu LiuWei-Guang Gu & Yi-Yu Lu. (2022) Elevated pretreatment neutrophil-to-lymphocyte ratio indicate low survival rate in apatinib-treated patients with non-small cell lung cancer: A STROBE-compliant article. Medicine 101:47, pages e32043.
Crossref
Yu-Ming Wang, Xin Xu, Jian Tang, Zhi-Yong Sun, Yu-Jie Fu, Xiao-Jing Zhao, Xiu-Mei Ma & Qing Ye. (2021) Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR pathway in esophageal squamous cell carcinoma. Cell & Bioscience 11:1.
Crossref
Caiyun Nie, Huifang Lv, Yishu Xing, Beibei Chen, Weifeng Xu, Jianzheng Wang & Xiaobing Chen. (2021) The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study. BMC Cancer 21:1.
Crossref
Chao Hou, Zhuang-Zhuang Jiang, Bo Pan, Xiao-Chun Zhang & Yan-Qing Liu. (2021) A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine 2021, pages 1-14.
Crossref
Ning Li, Ziyi Wang, Guangwen Yuan, Yangchun Sun, Rong Zhang, Xiaoguang Li, Nan Li, Jing Wang & Lingying Wu. (2020) An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study. Journal of Oncology 2020, pages 1-6.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.